Related Content
- Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
- Insulin combination treats low blood sugar in diabetes patients, study finds
- Adherence among chronic disease patients can lead to big savings
- IAF: 10 U.S. states will see highest diabetes prevalence, cost
- Mylan's generic Precose gets green light from FDA
PRINCETON, N.J. — The Food and Drug Administration has approved a treatment for Type 1 diabetes in children ages 2 to 5 years.
Drug maker Novo Nordisk announced Tuesday the additional approval of Levemir (insulin detemir [rDNA origin]). The insulin already was approved for Type 1 diabetes in older children and adults and Type 2 diabetes in adults, and the drug maker said the new FDA approval made Levemir the only basal insulin analog for use in the 2 to 5 year age group.
"Our biggest challenges and top priorities when treating some of the youngest children with Type 1 diabetes are safety and reducing the risk of hypoglycemia," said, Mark Sperling, editor-in-chief of the journal Pediatric Diabetes, referring to low blood sugar. "Levemir, with its approval from the FDA, is a particularly welcome addition to our treatment options for some of our youngest patients with Type 1 diabetes."
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
